Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jan-Dec:18:17534666241253945.
doi: 10.1177/17534666241253945.

Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders

Francesco Amati  1   2 , Gloria Leonardi  3 , Martina Contarini  4 , Letizia Corinna Morlacchi  3   4 , Anna Stainer  5   2 , Giovanna Pizzamiglio  4 , Stefano Aliberti  5   2 , Francesco Blasi  3   4 , Andrea Gramegna  3   4
Affiliations
Observational Study

Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders

Francesco Amati et al. Ther Adv Respir Dis. 2024 Jan-Dec.

Abstract

Background: Immunodeficiencies (IDs) are conditions caused by immune system dysfunctions which predispose to chronic infections. Cystic fibrosis (CF) patients are characterized by the presence of bronchiectasis filled with hyper-viscous secretions that constitute the ideal environment for infections. Although CF and IDs might share similarities in the pathophysiological mechanism of bronchiectasis development, they each offer different treatment options. We hypothesize that the introduction of a bundle of tests would increase the number of ID diagnoses among adults with Cystic Fibrosis Transmembrane conductance Regulator (CFTR) dysfunction.

Objectives: The primary objectives of this study were (1) assessing the prevalence of IDs in CF and (2) defining clinical characteristics of adults with both CF and IDs. The secondary objectives were: (1) assessing the prevalence of IDs in CFTR-Related Disorder (CFTR-RD) patients; (2) comparing the prevalence of IDs in CF and CFTR-RD; (3) comparing the prevalence of treatable IDs in CF and CFTR-RD.

Design: We conducted an observational, prospective, consecutive study on a cohort of 190 adult patients affected by CF or CFTR-RD.

Methods: Blood samples underwent a standardized immunological screening, including complete white blood count, IgG, IgA, IgM, IgG subclasses, total IgE, lymphocyte subsets, and HIV test. Comprehensive clinical history was assessed to identify risk factors for secondary IDs.

Results: We identify a high prevalence of immunodeficiencies among the entire cohort: 34 (20.1%) CF patients and 10 (47.6%) CFTR-RD patients are diagnosed with IDs via a blood screening. No statistically significant difference in terms of clinical characteristics was found between immunocompromised and immunocompetent CF patients.

Conclusion: We identify a high prevalence of immunodeficiencies in both CF and CFTR-RD.

Keywords: bronchiectasis; cystic fibrosis; immunodeficiencies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

    1. Sanders DB, Fink AK. Background and epidemiology. Pediatr Clin North Am 2016; 63: 567–584. - PMC - PubMed
    1. Wei T, Sui H, Su Y, et al.. Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: from technical improvement to clinical applications (Review). Mol Med Rep 2020; 22: 4992–5002. - PMC - PubMed
    1. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002; 15: 194–222. - PMC - PubMed
    1. McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: advances and challenges. Pediatr Pulmonol. 2022;57(Suppl. 1): S5–S12. - PMC - PubMed
    1. Schäfer J, Griese M, Chandrasekaran R, et al.. Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. BMC Pulm Med 2018; 18: 79. - PMC - PubMed

Publication types

MeSH terms

Substances